Zhongxing Liang1,2, Amber Feng3, Hyunsuk Shim4,5. 1. Department of Radiation Oncology, Emory University, Atlanta, GA, 30322, USA. zliang@emory.edu. 2. Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA. zliang@emory.edu. 3. Department of Radiation Oncology, Emory University, Atlanta, GA, 30322, USA. 4. Department of Radiation Oncology, Emory University, Atlanta, GA, 30322, USA. hshim@emory.edu. 5. Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA. hshim@emory.edu.
Abstract
PURPOSE: Although histone deacetylase (HDAC) inhibitors have been shown to effectively induce the inhibition of proliferation and migration in breast cancer, the mechanism of HDAC9's contribution to chemoresistance remains poorly understood. The aim of this study was to investigate the role of miR-30c-regulated HDAC9 in chemoresistance of breast cancer and to determine the potential of selective inhibition of HDAC9 in sensitizing resistant breast cancer cells to chemotherapy. METHODS: Expression levels of HDAC9 and miR-30c were measured in breast cancer cells and tissues using quantitative PCR analysis. The effect of selective inhibition of HDAC9 on sensitizing MDR cells to chemotherapy was assessed. MiR-30c/HDAC9 pathways' potential to mediate chemoresistance was analyzed. RESULTS: Our studies show that HDAC9 was significantly up-regulated in chemoresistant breast cancer cell lines compared to a chemosensitive cell line and was inversely correlated with the levels of miR-30c. MiR-30c mimics and HDAC9 inhibitors reversed the chemoresistance of multidrug-resistant breast cancer cells. CONCLUSIONS: These results indicate that the mechanism of chemoresistance reversal with selective HDAC inhibition was partially realized by regulating miR-30c via directly targeting HDAC9. Our findings suggest that the miR-30c/HDAC9 signaling axis could be a novel and potential therapeutic target in chemoresistant breast cancer.
PURPOSE: Although histone deacetylase (HDAC) inhibitors have been shown to effectively induce the inhibition of proliferation and migration in breast cancer, the mechanism of HDAC9's contribution to chemoresistance remains poorly understood. The aim of this study was to investigate the role of miR-30c-regulated HDAC9 in chemoresistance of breast cancer and to determine the potential of selective inhibition of HDAC9 in sensitizing resistant breast cancer cells to chemotherapy. METHODS: Expression levels of HDAC9 and miR-30c were measured in breast cancer cells and tissues using quantitative PCR analysis. The effect of selective inhibition of HDAC9 on sensitizing MDR cells to chemotherapy was assessed. MiR-30c/HDAC9 pathways' potential to mediate chemoresistance was analyzed. RESULTS: Our studies show that HDAC9 was significantly up-regulated in chemoresistant breast cancer cell lines compared to a chemosensitive cell line and was inversely correlated with the levels of miR-30c. MiR-30c mimics and HDAC9 inhibitors reversed the chemoresistance of multidrug-resistant breast cancer cells. CONCLUSIONS: These results indicate that the mechanism of chemoresistance reversal with selective HDAC inhibition was partially realized by regulating miR-30c via directly targeting HDAC9. Our findings suggest that the miR-30c/HDAC9 signaling axis could be a novel and potential therapeutic target in chemoresistant breast cancer.
Entities:
Keywords:
Breast cancer; Chemoresistance; HDAC inhibitor; HDAC9; MiR-30c
Authors: L M Butler; Y Webb; D B Agus; B Higgins; T R Tolentino; M C Kutko; M P LaQuaglia; M Drobnjak; C Cordon-Cardo; H I Scher; R Breslow; V M Richon; R A Rifkind; P A Marks Journal: Clin Cancer Res Date: 2001-04 Impact factor: 12.531